Aptamer Solutions Ltd

Activities: Pharmaceutical

Trending Articles

  1. IMPACT CKD model reveals the escalating toll of chronic kidney disease The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Isospec Analytics launches biomolecular analysis technology to identify unknown molecules The novel technology optimises the identification process of unknown molecules compared to mass analysis
  4. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
  5. ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Drug Delivery

Aptamer Group signs material agreement with genetic medicines company

Optimer binders will be developed to support targeted genetic medicines to specific cell types
Manufacturing

Aptamer and Neuro-Bio collaborate on Alzheimer’s disease diagnostic

The novel Alzheimer’s disease biomarker was discovered and is currently being further validated by Neuro-Bio, led by neuroscientist Baroness Susan Greenfield
Manufacturing

Aptamer launches reagent solution for immunohistochemistry

The Optimer-Fc is an antibody alternative for use within existing workflows replacing the primary, detecting, antibody
Drug Delivery

Aptamer partners with BaseCare Therapeutics

BaseCure Therapeutics is a pre-clinical stage biotech company dedicated to the discovery and development of innovative siRNA-based medicines
Manufacturing

Appointment of Interim Chief Commercial Officer, Aptamer Group

Derek joined the company in 2018 as Director of Global Sales
Drug Delivery

Aptamer Group's new deal supports novel therapies

Since the publication of the group’s full year results, the company has signed deals with a number of companies related to the development of Optimer solutions
Drug Delivery

Aptamer opens state-of-the-art laboratories in York, England

The new facilities will support the increased demand for Optimer technology
Subscribe now